Survival analysis of bevacizumab plus taxane treatment in luminal metastatic breast cancer.

Serafin Morales MurilloAriadna Gasol CudosJoel Veas RodriguezCarles Canosa MoralesJordi Melé OlivéFelip Vilardell VillellasDouglas Rene Sanchez GuzmanEdelmiro Iglesias MartínezAntonieta Salud Salvia

Published in: Future science OA (2021)

Paclitaxel plus bevacizumab combination is a useful treatment in metastatic luminal breast cancer with an impressive overall survival of 31 months, similar to combination to endocrine therapy and targeted therapy in first line. In patients with hormone resistance, endocrine therapy saw worse results thus the taxol plus bevacizumab combination could be a better option. This combination does not influence the results of subsequent treatments; therefore, it could provide a good option for patients.

Keyphrases

metastatic breast cancer
end stage renal disease
small cell lung cancer
metastatic colorectal cancer
chronic kidney disease
newly diagnosed
ejection fraction
peritoneal dialysis
stem cells
combination therapy
free survival
replacement therapy
cell therapy
childhood cancer